Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Steyr – page 17

449 clinical trials in Steyr, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Steyr at a glance
449
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

449 trials in Steyr

Open in trial search

Pancreatic carcinoma

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Coma

Not yet recruiting

Study to evaluate the effect of methylphenidate hydrochloride on the time to wake up in patients in a coma due to acute brain injury

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Methylphenidate Hydrochloride
  • Sponsor:Region Hovedstaden

Hereditary haemochromatosis

Not yet recruiting

A study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vamifeport trihydrochloride
  • Sponsor:CSL Behring LLC

Comparison of dupilumab and tezepelumab for the treatment of chronic rhinosinusitis with nasal polyps.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Medical University Of Vienna

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Regeneron Pharmaceuticals Inc.

Prostate cancer

Not yet recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Torl Biotherapeutics LLC

Non-small cell lung cancer

Not yet recruiting

Evaluation of Datopotamab Deruxtecan in Patients with Non-Squamous Non-Small Cell Lung Cancer and Active Brain Metastases

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Medica Scientia Innovation Research S.L.

Glioblastoma

Not yet recruiting

Study on Lomustine with or without Additional Brain Radiation for Patients with Recurrent Glioblastoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Non-small cell lung cancer+1

Not yet recruiting

Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Steyr

What the registry says about research in the country

01 Oncology - Blood Cancers

Innovative research focusing on multiple myeloma treatment approaches, including maintenance therapy post stem-cell transplantation and comparing different administration methods for targeted therapies. Studies also investigate new treatments for Hodgkin Lymphoma with emphasis on reducing toxicity while maintaining efficacy.

  • Multiple Myeloma Treatments
  • Hodgkin Lymphoma Therapy
  • Stem Cell Transplantation

Advanced clinical research evaluating novel drug combinations and administration routes to improve patient outcomes.

02 Breast Cancer Research

Comprehensive studies examining treatments for ER-positive, HER2-negative breast cancer, including both early-stage and advanced disease. Research focuses on novel therapeutic agents and extended treatment strategies to prevent recurrence.

  • Early Breast Cancer Treatment
  • Advanced Breast Cancer Therapy
  • Endocrine Therapy Innovation

Trials aim to improve current treatment standards and evaluate new therapeutic options for breast cancer patients.

03 Pain Management Studies

Extensive research into chronic pain conditions, including diabetic polyneuropathy, post-operative neuropathy, and chronic back pain. Studies evaluate new treatment approaches for various types of neuropathic and musculoskeletal pain.

  • Neuropathic Pain Treatment
  • Chronic Back Pain Management
  • Post-operative Pain Control

Investigations focus on developing effective add-on treatments for chronic pain conditions to improve patient quality of life.

04 Pancreatic Cancer Research

Advanced studies in metastatic pancreatic ductal adenocarcinoma, evaluating novel combination therapies to improve survival rates. Research focuses on comparing standard treatments with new therapeutic approaches.

  • Metastatic Disease Treatment
  • Combination Therapy Assessment
  • Survival Rate Improvement

Clinical trials aim to enhance treatment outcomes for patients with advanced pancreatic cancer.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.